Lemaitre Vascular (LMAT) 7.66 $LMAT
Dividend Challengers (And Near-Challengers): 67 Increases Expected By April 30
David Fish - at Seeking Alpha - Fri Feb 13, 7:16PM CST
KSS: 68.25 (-0.58), CNS: 41.45 (-0.70), PDCO: 50.65 (-0.16), NSU: 3.73 (+0.13), LYB: 89.99 (+0.19), MYE: 17.61 (+0.01), SCS: 18.43 (+0.07), PNC: 92.38 (+0.82), INDB: 40.25 (+0.03), MOV: 25.26 (-0.17), TMK: 54.05 (+0.35), ROIC: 17.27 (-0.08), TYC: 43.19 (+0.27), SYA: 22.86 (-0.14), SPTN: 25.99 (+0.14), ETN: 72.55 (+0.90), HMN: 31.40 (-0.11), ATLO: 24.93 (-0.06), SIG: 120.19 (+0.36), STWD: 24.24 (-0.10), IEX: 77.14 (+0.77), MJN: 101.89 (+2.32), BGS: 29.60 (-0.44), FCZA: 10.75 (+0.30), STJ: 67.48 (+0.65), MGA: 102.32 (-0.46), IEP: 100.21 (+0.28), MELI: 129.99 (-1.95), NRF: 18.65 (+0.12), OXM: 53.69 (-0.93), SNI: 73.00 (+0.39), LMAT: 7.66 (+0.08), PLOW: 21.90 (+0.32), FL: 53.96 (-0.13), EMCF: 24.03 (-0.87), BK: 39.20 (-0.21), HRC: 46.88 (+0.14), TXRH: 34.59 (+0.07), HD: 111.89 (-0.27), KW: 27.50 (+0.25), HSBC: 46.13 (-0.01), FMC: 63.68 (+0.44), LEA: 108.70 (-0.73), FFG: 58.39 (+0.25), RS: 55.14 (+1.36), HPY: 49.42 (-5.71), JWN: 79.41 (+0.04), FLS: 59.31 (+1.00), MTN: 85.85 (-0.82), ENH: 64.63 (+0.15), MLR: 21.11 (-0.08), CMCSA: 59.47 (+1.09), SSW: 18.50 (+0.45)
LeMaitre Vascular to Attend the BTIG Medical Technology, Diagnostics, and Healthcare IT Conference on Wednesday, February 18, 2015
GlobeNewswire - Fri Feb 13, 2:05PM CST
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will be participating in the Annual BTIG Medical Technology, Diagnostics, and Healthcare IT Conference at the Cliff Lodge in Snowbird, UT on Wednesday, February 18, 2015. JJ Pellegrino, Chief Financial Officer, will provide an update on the Company.
LMAT: 7.66 (+0.08)
Dividend Challengers (And Near-Challengers): 98 Increases Expected By The End Of March
David Fish - at Seeking Alpha - Wed Jan 14, 11:11PM CST
KSS: 68.25 (-0.58), HOG: 63.90 (+0.82), LAZ: 50.90 (+0.18), CNS: 41.45 (-0.70), AIV: 38.55 (-0.50), CNP: 21.76 (-0.35), AIT: 42.60 (+0.09), HOT: 78.55 (+0.67), MAT: 27.61 (+0.17), AJG: 47.50 (+0.27), INDB: 40.25 (+0.03), HME: 67.76 (-0.96), ETN: 72.55 (+0.90), CHSP: 36.98 (-0.12), HMN: 31.40 (-0.11), IR: 67.69 (+0.06), ALL: 71.46 (-0.11), FLIR: 33.01 (-0.23), MJN: 101.89 (+2.32), BGS: 29.60 (-0.44), CPA: 119.12 (+0.27), MGA: 102.32 (-0.46), IEP: 100.21 (+0.28), MELI: 129.99 (-1.95), EWBC: 40.60 (+0.37), MKTX: 81.22 (-0.66), CPT: 75.24 (-1.03), BLK: 376.04 (+1.16), CCE: 43.69 (-0.66), DPS: 76.95 (-1.35), CME: 93.92 (-1.39), ANTM: 141.05 (-0.95), ATVI: 23.11 (+0.17), FCF: 8.62 (-0.10), GMT: 60.08 (-0.44), LMAT: 7.66 (+0.08), ALE: 53.65 (-1.17), EMCF: 24.03 (-0.87), EPR: 61.68 (-0.30), HRC: 46.88 (+0.14), CMS: 34.65 (-0.88), HD: 111.89 (-0.27), KW: 27.50 (+0.25), FMC: 63.68 (+0.44), HSBC: 46.13 (-0.01), ATK: 140.03 (+0.78), EFX: 92.56 (-0.18), LEA: 108.70 (-0.73), FINL: 23.51 (-0.32), FFG: 58.39 (+0.25), LB: 94.51 (-0.30), HPY: 49.42 (-5.71), DNB: 133.27 (+0.46), BIP: 46.20 (-0.21), FIBK: 26.15 (+0.06), JWN: 79.41 (+0.04), FLS: 59.31 (+1.00), CEB: 79.35 (+0.93), ENH: 64.63 (+0.15), CMCSA: 59.47 (+1.09), CNA: 43.40 (+0.18)
LeMaitre Vascular to Attend the Sidoti & Company Emerging Growth Institutional Investor Forum on Monday, January 12, 2015
GlobeNewswire - Wed Jan 07, 12:41PM CST
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will be participating in the Sidoti & Company, LLC, Emerging Growth Institutional Investor Forum at the Grand Hyatt Hotel in New York, NY on Monday, January 12, 2015. JJ Pellegrino, Chief Financial Officer, will provide an update on the Company.
LMAT: 7.66 (+0.08)
Insider Trading Alert - DST, LMAT And LTS Traded By Insiders
at The Street - Tue Jan 06, 10:15AM CST
Stocks with insider trader activity include DST, LMAT and LTS
LMAT: 7.66 (+0.08), LTS: 3.92 (-0.02), DST: 108.31 (-0.35)
LeMaitre Vascular to Attend the Benchmark Micro Cap Discovery Conference on Thursday, December 11, 2014
GlobeNewswire - Thu Dec 04, 8:54AM CST
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will be participating in the Benchmark Company, LLC Micro Cap Discovery One-on-One Investor Conference at the Palmer House Hilton, Chicago, IL, on Thursday, December 11, 2014. David Roberts, President, will provide an update on the Company.
LMAT: 7.66 (+0.08)
MediPoint: Aortic Stent Grafts - South America Analysis and Market Forecasts
M2 - Thu Dec 04, 4:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/8b8djj/medipoint_aortic) has announced the addition of the "MediPoint: Aortic Stent Grafts - South America Analysis and Market Forecasts" report to their offering. Aortic stent grafts are most commonly used to reinforce a weak spot in an artery, which is known as an aneurysm. The stent grafts are designed to seal tightly with the patient's native artery above and below the aneurysm, and are used to treat abdominal aortic aneurysms as well as thoracic aortic aneurysms. Reasons to buy - Understand the trends shaping and driving the South America Aortic Stent Grafts market. - Realize device preferences of physicians who have performed the tests already. - Access market sizing, forecasts and quantified growth opportunities in South America Aortic Stent Grafts market through 2018. - Quantify candidate patient populations to better design product pricing & launch plans. - Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape. - Perform benchmarking analysis of growth opportunities against currently marketed products. - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market. Key Topics Covered: 1 List of Tables 2 Introduction 3 Industry Overview 4 Unmet Needs 5 Market Opportunity Analysis 6 Market Drivers, Barriers, and Substitutes 7 Competitive Assessment 8 Pipeline Assessment 9 Clinical Trials to Watch 10 Current and Future Players 11 Market Outlook 12 Appendix Companies Mentioned: - Altura Medical - Aptus Endosystems - B. Braun - Bolton Medical - Braile Biomedica - Cardiatis - Cook Medical - Endologix - Getinge Group - Gore Medical - Grikin Advanced Materials - Johnson & Johnson's Cordis Corporation - Jotec - LeMaitre Vascular - Lifetech Scientific - Lombard Medical - Medtronic - MicroPort Scientific Corporation - Nano Endoluminal - Terumo Corporation - TriVascular - Weike Medical Apparatus and Instrument - YTH Biological Material Scitech For more information visit http://www.researchandmarkets.com/research/8b...int_aortic
JNJ: 99.62 (+1.18), MDT: 75.26 (+0.33), EVAR: 5.47 (-0.07), LMAT: 7.66 (+0.08)
MediPoint: Aortic Stent Grafts - APAC Analysis and Market Forecasts
M2 - Thu Dec 04, 3:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/fxpfd4/medipoint_aortic) has announced the addition of the "MediPoint: Aortic Stent Grafts - APAC Analysis and Market Forecasts" report to their offering. Aortic stent grafts are most commonly used to reinforce a weak spot in an artery, which is known as an aneurysm. The stent grafts are designed to seal tightly with the patient's native artery above and below the aneurysm, and are used to treat abdominal aortic aneurysms as well as thoracic aortic aneurysms. Reasons to buy - Understand the trends shaping and driving the APAC Aortic Stent Grafts market. - Realize device preferences of physicians who have performed the tests already. - Access market sizing, forecasts and quantified growth opportunities in the APAC Aortic Stent Grafts market through 2018. - Quantify candidate patient populations to better design product pricing & launch plans. - Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape. - Perform benchmarking analysis of growth opportunities against currently marketed products. - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market. - Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth. Key Topics Covered: 1 List of Tables 2 Introduction 3 Industry Overview 4 Unmet Needs 5 Market Opportunity Analysis 6 Market Drivers, Barriers, and Substitutes 7 Competitive Assessment 8 Pipeline Assessment 9 Clinical Trials to Watch 10 Current and Future Players 11 Market Outlook 12 Appendix Companies Mentioned: - Altura - Aptus - B. Braun - Bolton - Braile Biomedica - Cardiatis - Cook - Endologix - Getinge - Gore - Grikin Advanced Materials - Johnson & Johnson's - Jotec - LeMaitre Vascular - Lifetech - Lombard - Medtronic - MicroPort Scientific - Nano Endoluminal - Terumo - TriVascular - Weike Medical Apparatus and Instrument - YTH Biological Material For more information visit http://www.researchandmarkets.com/research/fx...int_aortic
JNJ: 99.62 (+1.18), MDT: 75.26 (+0.33), LMAT: 7.66 (+0.08)
MediPoint: Aortic Stent Grafts - US Analysis and Market Forecasts 2013-2020
M2 - Mon Nov 24, 8:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/lvjkp8/medipoint_aortic) has announced the addition of the "MediPoint: Aortic Stent Grafts - US Analysis and Market Forecasts" report to their offering. Aortic stent grafts are most commonly used to reinforce a weak spot in an artery, which is known as an aneurysm. The stent grafts are designed to seal tightly with the patient's native artery above and below the aneurysm, and are used to treat abdominal aortic aneurysms as well as thoracic aortic aneurysms. Aortic aneurysms, as opposed to aneurysms found elsewhere in the body, are potentially very serious, as a burst aorta results in massive internal bleeding that can be fatal unless treated rapidly by an experienced emergency medical team. The US market is the largest market for aortic stent grafts, accounting for more than 40% of the global market. The US market is very similar to that of the global market with regard to the trends in market share. Gore Medical remains the leader in the US for both the EVAR and TEVAR markets. These three companies also offer market leading products for treating AAA and TAA, ensuring long-term, effective solutions to patients. Scope - An overview of Aortic Stent Grafts, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines. - Annualized the US Aortic Stent Grafts market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020. - Investigation of current and future market competition for Aortic Stent Grafts. - Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events. - Competitor assessment including device approval analysis and device sales forecasts. - Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast. - Analysis of unmet needs within the market and opportunities for future players. - Technology trends evaluation to assess strength of pipeline. - An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines. - Company profiles including business description, financial overview and SWOT analysis. - Coverage of key market players. - Strategic assessment of the Aortic Stent Grafts sector through market impact analysis, future market scenario and company analysis. - Direct quotes from Key Opinion Leaders (KOL) as well as doctors Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Industry Overview 4 Unmet Needs 5 Market Opportunity Analysis 6 Market Drivers, Barriers, and Substitutes 7 Competitive Assessment 8 Pipeline Assessment 9 Clinical Trials to Watch 10 Current and Future Players 11 Market Outlook 12 Appendix Companies Mentioned - Altura Medical - Aptus Endosystems - B. Braun - Bolton Medical - Braile Biom?dica - Cardiatis - Cook Medical - Endologix - Getinge Group - Gore Medical - Grikin Advanced Materials - Johnson & Johnson's Cordis Corporation - Jotec - LeMaitre Vascular - Lifetech Scientific - Lombard Medical - Medtronic - MicroPort Scientific Corporation - Nano Endoluminal - Terumo Corporation - TriVascular - Weike Medical Apparatus and Instrument - YTH Biological Material Scitech For more information visit http://www.researchandmarkets.com/research/lv...int_aortic
JNJ: 99.62 (+1.18), MDT: 75.26 (+0.33), EVAR: 5.47 (-0.07), LMAT: 7.66 (+0.08)
MediPoint: Aortic Stent Grafts - Current and Future Players
M2 - Tue Nov 18, 8:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/pk7mdq/medipoint_aortic) has announced the addition of the "MediPoint: Aortic Stent Grafts - Current and Future Players" report to their offering. The report identifies and analyzes the key companies shaping and driving the Aortic Stent Grafts market. The report provides insight into the competitive Aortic Stent Grafts landscape, including new companies entering the market and pipeline products in development. Scope - Investigation of current and future market competition for Aortic Stent Grafts. - Competitor assessment including device approval analysis. - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of the device sector through market impact analysis, future market scenario and company analysis. - Direct quotes from Key Opinion Leaders (KOL) as well as doctors using Aortic Stent Grafts in clinical practice. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Competitive Assessment 4 Pipeline Assessment 5 Current and Future Players 6 Appendix Companies Mentioned - Altura Medical - Aptus Endosystems - B. Braun - Bolton Medical - Braile Biom?dica - Cardiatis - Cook Medical - Endologix - Getinge Group - Gore Medical - Grikin Advanced Materials - Johnson & Johnson's Cordis Corporation - Jotec - LeMaitre Vascular - Lifetech Scientific - Lombard Medical - Medtronic - MicroPort Scientific Corporation - Nano Endoluminal - Terumo Corporation - TriVascular - Weike Medical Apparatus and Instrument - YTH Biological Material Scitech For more information visit http://www.researchandmarkets.com/research/pk...int_aortic
JNJ: 99.62 (+1.18), MDT: 75.26 (+0.33), EVAR: 5.47 (-0.07), LMAT: 7.66 (+0.08)
LeMaitre Vascular to Participate in Three Investor Conferences in November 2014
GlobeNewswire - Wed Nov 12, 2:58PM CST
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will be participating in three upcoming investor conferences in New York City in November.
LMAT: 7.66 (+0.08)
U.S. Market for Peripheral Vascular Devices and Accessories Executive Summary: By 2020, the U.S. market for peripheral vascular devices will be worth over $6 billion
M2 - Tue Nov 11, 6:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/3rwwd3/u_s_market_for) has announced the addition of the "U.S. Market for Peripheral Vascular Devices and Accessories (Executive Summary)" report to their offering. The peripheral vascular device market includes stents, percutaneous transluminal angioplasty (PTA) balloon catheters, atherectomy devices, chronic total occlusion devices, stent grafts, surgical grafts, arteriovenous (AV) access thrombectomy devices, inferior vena cava filters, catheters, guidewires, introducer sheaths, vascular closure devices and transcatheter embolization devices. These devices can be used for treating either coronary arterial or peripheral arterial disease (PAD), but only those devices used for peripheral procedures are included in this report. Older individuals and those who are obese have a higher risk of developing PAD. As result of a general increase in peripheral procedures and the development of new lower-limb treatments, the market for products such as stents and stent grafts will grow rapidly in the U.S. over the forecast period. Peripheral artery disease (PAD) remains a significantly under treated condition in the U.S and PAD is the leading cause of leg amputation. These factors will continue to drive growth in the peripheral vascular device market. In particular, the peripheral stent market is projected to grow over the forecast period. However, intense competition has led to price erosion and market penetration has moderated this once high growth segment. The launch of new technologies, including drug-eluting stents, will generate marginal revenues and only one company has sought FDA approval. In contrast, significant investments and acquisitions have taken place in the efforts of bringing the first drug-eluting balloon to the market, with Medtronic and C. R. Bard in a tight race to gain approval. Scope - Competitor Analysis - Identified Strategic Opportunities - Market Overview by Segment - Trend Analysis by Segment - Market Drivers & Limiters - Mergers & Acquisitions - Customer Feedback and Market Monitoring Main Segments Included: - Peripheral Vascular Stent Market - PTA Balloon Catheter Market - Atherectomy Device Market - Chronic Total Occlusion (CTO) Device Market - Embolic Protection Device Market - Stent Graft Market - Surgical Graft Market - AV Access Thrombectomy Device Market - Inferior Vena Cava Filter Market - Diagnostic and Interventional Catheter Market - Diagnostic and Interventional Guidewire Market - Introducer Sheath Market - Vascular Closure Device Market - Transcatheter Embolization Device Market Companies Mentioned - ALN International Inc. - Abbott Laboratories - AccessClosure - AngioDynamics - AngioScore - Angiotech - Argon Medical - Arstasis - Artegraft - Asahi Intecc USA - Atrax - Atrium Medical - B. Braun - Boston Scientific - C. R. Bard - Cardiovascular Systems Inc - Cardiva CeloNova Biosciences - Cook Medical - Cordis - Covidien - Endologix - IDEV Technologies - LeMaitre Vascular - MEDRAD - Maquet - Marine Polymer Technologies - Medtronic - Morris Innovative - Penumbra - Pfizer For more information visit http://www.researchandmarkets.com/research/3r...market_for About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BSX: 14.98 (+0.24), ABT: 46.09 (+0.87), MDT: 75.26 (+0.33), CSII: 35.69 (+0.17), LMAT: 7.66 (+0.08)
LeMaitre ups earnings 43% in Q3
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 9:21AM CDT
LMAT: 7.66 (+0.08)
LeMaitre Vascular's (LMAT) CEO George LeMaitre on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Oct 28, 10:29PM CDT
LMAT: 7.66 (+0.08)
LeMaitre Vascular declares $0.035 dividend
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 4:45PM CDT
LMAT: 7.66 (+0.08)
LeMaitre Vascular EPS in-line, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 3:56PM CDT
LMAT: 7.66 (+0.08)
LeMaitre Vascular (LMAT) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Oct 28, 3:55PM CDT
LMAT: 7.66 (+0.08)
LeMaitre Q3 2014 Sales $17.5mm (+14%) ; Op. Income $1.9mm (+139%)
GlobeNewswire - Tue Oct 28, 3:05PM CDT
LeMaitre Vascular, Inc. (Nasdaq:LMAT) today reported Q3 2014 results, provided guidance and announced a $0.035/share dividend.
LMAT: 7.66 (+0.08)
LeMaitre Vascular Will Announce Third Quarter 2014 Earnings Results on October 28, 2014
GlobeNewswire - Tue Oct 21, 10:58AM CDT
LeMaitre Vascular, Inc. (Nasdaq:LMAT), announced today that it will release its third quarter 2014 financial results on October 28, 2014, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook.
LMAT: 7.66 (+0.08)
Dividend Challengers (And Near-Challengers): 67 Increases Expected By April 30
David Fish - at Seeking Alpha - Fri Feb 13, 7:16PM CST
KSS: 68.25 (-0.58), CNS: 41.45 (-0.70), PDCO: 50.65 (-0.16), NSU: 3.73 (+0.13), LYB: 89.99 (+0.19), MYE: 17.61 (+0.01), SCS: 18.43 (+0.07), PNC: 92.38 (+0.82), INDB: 40.25 (+0.03), MOV: 25.26 (-0.17), TMK: 54.05 (+0.35), ROIC: 17.27 (-0.08), TYC: 43.19 (+0.27), SYA: 22.86 (-0.14), SPTN: 25.99 (+0.14), ETN: 72.55 (+0.90), HMN: 31.40 (-0.11), ATLO: 24.93 (-0.06), SIG: 120.19 (+0.36), STWD: 24.24 (-0.10), IEX: 77.14 (+0.77), MJN: 101.89 (+2.32), BGS: 29.60 (-0.44), FCZA: 10.75 (+0.30), STJ: 67.48 (+0.65), MGA: 102.32 (-0.46), IEP: 100.21 (+0.28), MELI: 129.99 (-1.95), NRF: 18.65 (+0.12), OXM: 53.69 (-0.93), SNI: 73.00 (+0.39), LMAT: 7.66 (+0.08), PLOW: 21.90 (+0.32), FL: 53.96 (-0.13), EMCF: 24.03 (-0.87), BK: 39.20 (-0.21), HRC: 46.88 (+0.14), TXRH: 34.59 (+0.07), HD: 111.89 (-0.27), KW: 27.50 (+0.25), HSBC: 46.13 (-0.01), FMC: 63.68 (+0.44), LEA: 108.70 (-0.73), FFG: 58.39 (+0.25), RS: 55.14 (+1.36), HPY: 49.42 (-5.71), JWN: 79.41 (+0.04), FLS: 59.31 (+1.00), MTN: 85.85 (-0.82), ENH: 64.63 (+0.15), MLR: 21.11 (-0.08), CMCSA: 59.47 (+1.09), SSW: 18.50 (+0.45)
LeMaitre Vascular to Attend the BTIG Medical Technology, Diagnostics, and Healthcare IT Conference on Wednesday, February 18, 2015
GlobeNewswire - Fri Feb 13, 2:05PM CST
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will be participating in the Annual BTIG Medical Technology, Diagnostics, and Healthcare IT Conference at the Cliff Lodge in Snowbird, UT on Wednesday, February 18, 2015. JJ Pellegrino, Chief Financial Officer, will provide an update on the Company.
LMAT: 7.66 (+0.08)
Dividend Challengers (And Near-Challengers): 98 Increases Expected By The End Of March
David Fish - at Seeking Alpha - Wed Jan 14, 11:11PM CST
KSS: 68.25 (-0.58), HOG: 63.90 (+0.82), LAZ: 50.90 (+0.18), CNS: 41.45 (-0.70), AIV: 38.55 (-0.50), CNP: 21.76 (-0.35), AIT: 42.60 (+0.09), HOT: 78.55 (+0.67), MAT: 27.61 (+0.17), AJG: 47.50 (+0.27), INDB: 40.25 (+0.03), HME: 67.76 (-0.96), ETN: 72.55 (+0.90), CHSP: 36.98 (-0.12), HMN: 31.40 (-0.11), IR: 67.69 (+0.06), ALL: 71.46 (-0.11), FLIR: 33.01 (-0.23), MJN: 101.89 (+2.32), BGS: 29.60 (-0.44), CPA: 119.12 (+0.27), MGA: 102.32 (-0.46), IEP: 100.21 (+0.28), MELI: 129.99 (-1.95), EWBC: 40.60 (+0.37), MKTX: 81.22 (-0.66), CPT: 75.24 (-1.03), BLK: 376.04 (+1.16), CCE: 43.69 (-0.66), DPS: 76.95 (-1.35), CME: 93.92 (-1.39), ANTM: 141.05 (-0.95), ATVI: 23.11 (+0.17), FCF: 8.62 (-0.10), GMT: 60.08 (-0.44), LMAT: 7.66 (+0.08), ALE: 53.65 (-1.17), EMCF: 24.03 (-0.87), EPR: 61.68 (-0.30), HRC: 46.88 (+0.14), CMS: 34.65 (-0.88), HD: 111.89 (-0.27), KW: 27.50 (+0.25), FMC: 63.68 (+0.44), HSBC: 46.13 (-0.01), ATK: 140.03 (+0.78), EFX: 92.56 (-0.18), LEA: 108.70 (-0.73), FINL: 23.51 (-0.32), FFG: 58.39 (+0.25), LB: 94.51 (-0.30), HPY: 49.42 (-5.71), DNB: 133.27 (+0.46), BIP: 46.20 (-0.21), FIBK: 26.15 (+0.06), JWN: 79.41 (+0.04), FLS: 59.31 (+1.00), CEB: 79.35 (+0.93), ENH: 64.63 (+0.15), CMCSA: 59.47 (+1.09), CNA: 43.40 (+0.18)
LeMaitre Vascular to Attend the Sidoti & Company Emerging Growth Institutional Investor Forum on Monday, January 12, 2015
GlobeNewswire - Wed Jan 07, 12:41PM CST
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will be participating in the Sidoti & Company, LLC, Emerging Growth Institutional Investor Forum at the Grand Hyatt Hotel in New York, NY on Monday, January 12, 2015. JJ Pellegrino, Chief Financial Officer, will provide an update on the Company.
LMAT: 7.66 (+0.08)
Insider Trading Alert - DST, LMAT And LTS Traded By Insiders
at The Street - Tue Jan 06, 10:15AM CST
Stocks with insider trader activity include DST, LMAT and LTS
LMAT: 7.66 (+0.08), LTS: 3.92 (-0.02), DST: 108.31 (-0.35)
LeMaitre Vascular to Attend the Benchmark Micro Cap Discovery Conference on Thursday, December 11, 2014
GlobeNewswire - Thu Dec 04, 8:54AM CST
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will be participating in the Benchmark Company, LLC Micro Cap Discovery One-on-One Investor Conference at the Palmer House Hilton, Chicago, IL, on Thursday, December 11, 2014. David Roberts, President, will provide an update on the Company.
LMAT: 7.66 (+0.08)
MediPoint: Aortic Stent Grafts - South America Analysis and Market Forecasts
M2 - Thu Dec 04, 4:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/8b8djj/medipoint_aortic) has announced the addition of the "MediPoint: Aortic Stent Grafts - South America Analysis and Market Forecasts" report to their offering. Aortic stent grafts are most commonly used to reinforce a weak spot in an artery, which is known as an aneurysm. The stent grafts are designed to seal tightly with the patient's native artery above and below the aneurysm, and are used to treat abdominal aortic aneurysms as well as thoracic aortic aneurysms. Reasons to buy - Understand the trends shaping and driving the South America Aortic Stent Grafts market. - Realize device preferences of physicians who have performed the tests already. - Access market sizing, forecasts and quantified growth opportunities in South America Aortic Stent Grafts market through 2018. - Quantify candidate patient populations to better design product pricing & launch plans. - Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape. - Perform benchmarking analysis of growth opportunities against currently marketed products. - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market. Key Topics Covered: 1 List of Tables 2 Introduction 3 Industry Overview 4 Unmet Needs 5 Market Opportunity Analysis 6 Market Drivers, Barriers, and Substitutes 7 Competitive Assessment 8 Pipeline Assessment 9 Clinical Trials to Watch 10 Current and Future Players 11 Market Outlook 12 Appendix Companies Mentioned: - Altura Medical - Aptus Endosystems - B. Braun - Bolton Medical - Braile Biomedica - Cardiatis - Cook Medical - Endologix - Getinge Group - Gore Medical - Grikin Advanced Materials - Johnson & Johnson's Cordis Corporation - Jotec - LeMaitre Vascular - Lifetech Scientific - Lombard Medical - Medtronic - MicroPort Scientific Corporation - Nano Endoluminal - Terumo Corporation - TriVascular - Weike Medical Apparatus and Instrument - YTH Biological Material Scitech For more information visit http://www.researchandmarkets.com/research/8b...int_aortic
JNJ: 99.62 (+1.18), MDT: 75.26 (+0.33), EVAR: 5.47 (-0.07), LMAT: 7.66 (+0.08)
MediPoint: Aortic Stent Grafts - APAC Analysis and Market Forecasts
M2 - Thu Dec 04, 3:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/fxpfd4/medipoint_aortic) has announced the addition of the "MediPoint: Aortic Stent Grafts - APAC Analysis and Market Forecasts" report to their offering. Aortic stent grafts are most commonly used to reinforce a weak spot in an artery, which is known as an aneurysm. The stent grafts are designed to seal tightly with the patient's native artery above and below the aneurysm, and are used to treat abdominal aortic aneurysms as well as thoracic aortic aneurysms. Reasons to buy - Understand the trends shaping and driving the APAC Aortic Stent Grafts market. - Realize device preferences of physicians who have performed the tests already. - Access market sizing, forecasts and quantified growth opportunities in the APAC Aortic Stent Grafts market through 2018. - Quantify candidate patient populations to better design product pricing & launch plans. - Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape. - Perform benchmarking analysis of growth opportunities against currently marketed products. - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market. - Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth. Key Topics Covered: 1 List of Tables 2 Introduction 3 Industry Overview 4 Unmet Needs 5 Market Opportunity Analysis 6 Market Drivers, Barriers, and Substitutes 7 Competitive Assessment 8 Pipeline Assessment 9 Clinical Trials to Watch 10 Current and Future Players 11 Market Outlook 12 Appendix Companies Mentioned: - Altura - Aptus - B. Braun - Bolton - Braile Biomedica - Cardiatis - Cook - Endologix - Getinge - Gore - Grikin Advanced Materials - Johnson & Johnson's - Jotec - LeMaitre Vascular - Lifetech - Lombard - Medtronic - MicroPort Scientific - Nano Endoluminal - Terumo - TriVascular - Weike Medical Apparatus and Instrument - YTH Biological Material For more information visit http://www.researchandmarkets.com/research/fx...int_aortic
JNJ: 99.62 (+1.18), MDT: 75.26 (+0.33), LMAT: 7.66 (+0.08)
MediPoint: Aortic Stent Grafts - US Analysis and Market Forecasts 2013-2020
M2 - Mon Nov 24, 8:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/lvjkp8/medipoint_aortic) has announced the addition of the "MediPoint: Aortic Stent Grafts - US Analysis and Market Forecasts" report to their offering. Aortic stent grafts are most commonly used to reinforce a weak spot in an artery, which is known as an aneurysm. The stent grafts are designed to seal tightly with the patient's native artery above and below the aneurysm, and are used to treat abdominal aortic aneurysms as well as thoracic aortic aneurysms. Aortic aneurysms, as opposed to aneurysms found elsewhere in the body, are potentially very serious, as a burst aorta results in massive internal bleeding that can be fatal unless treated rapidly by an experienced emergency medical team. The US market is the largest market for aortic stent grafts, accounting for more than 40% of the global market. The US market is very similar to that of the global market with regard to the trends in market share. Gore Medical remains the leader in the US for both the EVAR and TEVAR markets. These three companies also offer market leading products for treating AAA and TAA, ensuring long-term, effective solutions to patients. Scope - An overview of Aortic Stent Grafts, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines. - Annualized the US Aortic Stent Grafts market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020. - Investigation of current and future market competition for Aortic Stent Grafts. - Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events. - Competitor assessment including device approval analysis and device sales forecasts. - Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast. - Analysis of unmet needs within the market and opportunities for future players. - Technology trends evaluation to assess strength of pipeline. - An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines. - Company profiles including business description, financial overview and SWOT analysis. - Coverage of key market players. - Strategic assessment of the Aortic Stent Grafts sector through market impact analysis, future market scenario and company analysis. - Direct quotes from Key Opinion Leaders (KOL) as well as doctors Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Industry Overview 4 Unmet Needs 5 Market Opportunity Analysis 6 Market Drivers, Barriers, and Substitutes 7 Competitive Assessment 8 Pipeline Assessment 9 Clinical Trials to Watch 10 Current and Future Players 11 Market Outlook 12 Appendix Companies Mentioned - Altura Medical - Aptus Endosystems - B. Braun - Bolton Medical - Braile Biom?dica - Cardiatis - Cook Medical - Endologix - Getinge Group - Gore Medical - Grikin Advanced Materials - Johnson & Johnson's Cordis Corporation - Jotec - LeMaitre Vascular - Lifetech Scientific - Lombard Medical - Medtronic - MicroPort Scientific Corporation - Nano Endoluminal - Terumo Corporation - TriVascular - Weike Medical Apparatus and Instrument - YTH Biological Material Scitech For more information visit http://www.researchandmarkets.com/research/lv...int_aortic
JNJ: 99.62 (+1.18), MDT: 75.26 (+0.33), EVAR: 5.47 (-0.07), LMAT: 7.66 (+0.08)
MediPoint: Aortic Stent Grafts - Current and Future Players
M2 - Tue Nov 18, 8:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/pk7mdq/medipoint_aortic) has announced the addition of the "MediPoint: Aortic Stent Grafts - Current and Future Players" report to their offering. The report identifies and analyzes the key companies shaping and driving the Aortic Stent Grafts market. The report provides insight into the competitive Aortic Stent Grafts landscape, including new companies entering the market and pipeline products in development. Scope - Investigation of current and future market competition for Aortic Stent Grafts. - Competitor assessment including device approval analysis. - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of the device sector through market impact analysis, future market scenario and company analysis. - Direct quotes from Key Opinion Leaders (KOL) as well as doctors using Aortic Stent Grafts in clinical practice. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Competitive Assessment 4 Pipeline Assessment 5 Current and Future Players 6 Appendix Companies Mentioned - Altura Medical - Aptus Endosystems - B. Braun - Bolton Medical - Braile Biom?dica - Cardiatis - Cook Medical - Endologix - Getinge Group - Gore Medical - Grikin Advanced Materials - Johnson & Johnson's Cordis Corporation - Jotec - LeMaitre Vascular - Lifetech Scientific - Lombard Medical - Medtronic - MicroPort Scientific Corporation - Nano Endoluminal - Terumo Corporation - TriVascular - Weike Medical Apparatus and Instrument - YTH Biological Material Scitech For more information visit http://www.researchandmarkets.com/research/pk...int_aortic
JNJ: 99.62 (+1.18), MDT: 75.26 (+0.33), EVAR: 5.47 (-0.07), LMAT: 7.66 (+0.08)
LeMaitre Vascular to Participate in Three Investor Conferences in November 2014
GlobeNewswire - Wed Nov 12, 2:58PM CST
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will be participating in three upcoming investor conferences in New York City in November.
LMAT: 7.66 (+0.08)
U.S. Market for Peripheral Vascular Devices and Accessories Executive Summary: By 2020, the U.S. market for peripheral vascular devices will be worth over $6 billion
M2 - Tue Nov 11, 6:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/3rwwd3/u_s_market_for) has announced the addition of the "U.S. Market for Peripheral Vascular Devices and Accessories (Executive Summary)" report to their offering. The peripheral vascular device market includes stents, percutaneous transluminal angioplasty (PTA) balloon catheters, atherectomy devices, chronic total occlusion devices, stent grafts, surgical grafts, arteriovenous (AV) access thrombectomy devices, inferior vena cava filters, catheters, guidewires, introducer sheaths, vascular closure devices and transcatheter embolization devices. These devices can be used for treating either coronary arterial or peripheral arterial disease (PAD), but only those devices used for peripheral procedures are included in this report. Older individuals and those who are obese have a higher risk of developing PAD. As result of a general increase in peripheral procedures and the development of new lower-limb treatments, the market for products such as stents and stent grafts will grow rapidly in the U.S. over the forecast period. Peripheral artery disease (PAD) remains a significantly under treated condition in the U.S and PAD is the leading cause of leg amputation. These factors will continue to drive growth in the peripheral vascular device market. In particular, the peripheral stent market is projected to grow over the forecast period. However, intense competition has led to price erosion and market penetration has moderated this once high growth segment. The launch of new technologies, including drug-eluting stents, will generate marginal revenues and only one company has sought FDA approval. In contrast, significant investments and acquisitions have taken place in the efforts of bringing the first drug-eluting balloon to the market, with Medtronic and C. R. Bard in a tight race to gain approval. Scope - Competitor Analysis - Identified Strategic Opportunities - Market Overview by Segment - Trend Analysis by Segment - Market Drivers & Limiters - Mergers & Acquisitions - Customer Feedback and Market Monitoring Main Segments Included: - Peripheral Vascular Stent Market - PTA Balloon Catheter Market - Atherectomy Device Market - Chronic Total Occlusion (CTO) Device Market - Embolic Protection Device Market - Stent Graft Market - Surgical Graft Market - AV Access Thrombectomy Device Market - Inferior Vena Cava Filter Market - Diagnostic and Interventional Catheter Market - Diagnostic and Interventional Guidewire Market - Introducer Sheath Market - Vascular Closure Device Market - Transcatheter Embolization Device Market Companies Mentioned - ALN International Inc. - Abbott Laboratories - AccessClosure - AngioDynamics - AngioScore - Angiotech - Argon Medical - Arstasis - Artegraft - Asahi Intecc USA - Atrax - Atrium Medical - B. Braun - Boston Scientific - C. R. Bard - Cardiovascular Systems Inc - Cardiva CeloNova Biosciences - Cook Medical - Cordis - Covidien - Endologix - IDEV Technologies - LeMaitre Vascular - MEDRAD - Maquet - Marine Polymer Technologies - Medtronic - Morris Innovative - Penumbra - Pfizer For more information visit http://www.researchandmarkets.com/research/3r...market_for About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BSX: 14.98 (+0.24), ABT: 46.09 (+0.87), MDT: 75.26 (+0.33), CSII: 35.69 (+0.17), LMAT: 7.66 (+0.08)
LeMaitre ups earnings 43% in Q3
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 9:21AM CDT
LMAT: 7.66 (+0.08)
LeMaitre Vascular's (LMAT) CEO George LeMaitre on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Oct 28, 10:29PM CDT
LMAT: 7.66 (+0.08)
LeMaitre Vascular declares $0.035 dividend
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 4:45PM CDT
LMAT: 7.66 (+0.08)
LeMaitre Vascular EPS in-line, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 3:56PM CDT
LMAT: 7.66 (+0.08)
LeMaitre Vascular (LMAT) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Oct 28, 3:55PM CDT
LMAT: 7.66 (+0.08)
LeMaitre Q3 2014 Sales $17.5mm (+14%) ; Op. Income $1.9mm (+139%)
GlobeNewswire - Tue Oct 28, 3:05PM CDT
LeMaitre Vascular, Inc. (Nasdaq:LMAT) today reported Q3 2014 results, provided guidance and announced a $0.035/share dividend.
LMAT: 7.66 (+0.08)
LeMaitre Vascular Will Announce Third Quarter 2014 Earnings Results on October 28, 2014
GlobeNewswire - Tue Oct 21, 10:58AM CDT
LeMaitre Vascular, Inc. (Nasdaq:LMAT), announced today that it will release its third quarter 2014 financial results on October 28, 2014, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook.
LMAT: 7.66 (+0.08)
